Sulphasalazine in rheumatoid arthritis: desensitising the patient with a skin rash.
Sulphasalazine has been shown to be useful in the management of rheumatoid arthritis. However, its use may be complicated by a skin rash. Eight patients with a rash have undergone desensitisation, the aim of which was to achieve a daily dose of 2 g sulphasalazine. This was successful in five patients, partially successful in two, and failed in one patient. Desensitisation to sulphasalazine is a simple outpatient procedure, which subsequently allows the majority of patients developing a skin rash to continue treatment.
Bax
D E
DE
Amos
R S
RS
D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D003888:Desensitization, Immunologic; D003875:Drug Eruptions / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D012460:Sulfasalazine / Q000009:adverse effects* / Q000627:therapeutic use
D012460:Sulfasalazine